

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity:	Elixinol Wellness Limited
ABN:	621 479 794

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ronald Dufficy
Date of last notice	6 April 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	1) 26 May 2023 2) 31 May 2023 3) 31 May 2023 4) 31 May 2023
No. of securities held prior to change	780,494 Fully paid Ordinary Shares 1,914,515 Performance Share Rights
Class	1) Fully paid ordinary shares 2) Salary Sacrifice rights 3) Performance Share Rights 4) Performance Share Rights - Retention Share Rights

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number acquired	<ol style="list-style-type: none"> 1) 555,556 Fully paid Ordinary Shares 2) 3,611,112 Salary Sacrifice rights 3) 3,478,785 Performance Share Rights 4) 1,300,000 Performance Share Rights - Retention Share Rights
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	<ol style="list-style-type: none"> 1) Ordinary Shares - \$0.018 per share 2) Salary Sacrifice rights - issued in lieu of cash consideration with a deemed issue price of \$0.018 per Director Fee Right. 3) Performance Share Rights - issued in lieu of cash consideration for Mr Dufficy's FY2022 STI award with a deemed issue price of \$0.021 per Share Right. 4) Performance Share Rights - Retention Share Rights - issued in lieu of cash consideration as part of Mr Dufficy's remuneration with a deemed issue price of \$0.025 per Retention Share Right.
No. of securities held after change	1,336,050 Fully paid Ordinary Shares 6,693,300 Performance Share Rights 3,611,112 Salary Sacrifice rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<ol style="list-style-type: none"> 1) Fully paid ordinary shares issued under the Company's Share Purchase Plan 2) Salary Sacrifice rights approved by shareholders at the Company's Annual General Meeting on 31 May 2023 3) Performance Share Rights approved by shareholders at the Company's Annual General Meeting on 31 May 2023 4) Performance Share Rights - Retention Share Rights approved by shareholders at the Company's Annual General Meeting on 31 May 2023

Part 2 – Change of director's interests in contracts

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.